Daily Archives: October 14, 2020

Dublin, Oct. 12, 2020 (GLOBE NEWSWIRE) -- The "CF & CFRP Market by Source (Virgin, Recycled), Precursor (PAN, Pitch, Rayon), Resin (Thermosetting, Thermoplastic), Manufacturing Process, End-use Industry, and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global CF & CFRP market size is projected to grow from USD 17.5 billion in 2020 to USD 31.5 billion by 2025, at a CAGR of 12.4%

The CF & CFRP materials offer exceptional properties, such as low weight, stiffness, strength, tenacity, density, thermal & electrical conductivity, fatigue, and corrosion resistance. Owing to these outstanding properties, conventional materials, such as aluminum and steel, are less preferred in high-performance applications in various end-use industries, including aerospace & defense, wind energy, sporting goods, and among others. However, the global pandemic disease COVID-19 has forced the composite component manufacturers to shut down their operations partially, which is expected to decrease the demand for CF & CFRP in 2020.

The virgin carbon fiber segment of Carbon Fiber to be the fastest-growing segment.

The carbon fiber based on the source is segmented into virgin carbon fiber and recycled carbon fiber. Virgin is made from precursors such as PAN and pitch. These fibers find applications in various aerospace & defense, wind energy, sporting goods, and other industries. Virgin carbon fiber offers better thermal and mechanical properties than recycled carbon fiber. They are preferred over recycled carbon fiber in high-end aerospace applications.

PAN carbon fiber to be the faster-growing precursor type, in terms of value.

C PAN-based carbon fiber is a type of fiber produced by the carbonization of PAN precursor. Having high tensile strength and high elastic modulus, it is extensively used for structural material composites in aerospace & defense, automotive, and sporting goods industries. These properties are driving the use of PAN carbon fiber in various end-use industries.

Story continues

Owing to the COVID-19 pandemic, the new aircraft deliveries and wind energy installations are expected to reduce in 2020, which will result in reduced demand for PAN carbon fiber from these industries. The demand is expected to recover after 2020.

The thermoplastic segment to be the fastest-growing resin type, in terms of value, in the CF & CFRP market.

The application of thermoplastic polymer as a matrix material in CFRP composites has grown significantly in recent years. The thermoplastic resin is used with continuous fiber to create structural composite products. The main advantage of thermoplastic resin as matrix material is that, unlike thermoset resin, the composite formed can be reshaped and reformed. The composite formed is also easily recyclable. These factors are expected to drive the thermoplastic resin in the CFRP market during the forecast period.

The filament winding to be the fastest-growing manufacturing process, in terms of value, in the CF & CFRP market.

The filament winding process produces hollow or circular components such as compressed air tanks, high-pressure CO2 tanks & bottles, water softener systems, rescue air tanks, sailboat masts, CNG tanks, light poles, and other construction materials. This automated process is used to make highly engineered structures. The increased demand for CFRP from CNG and CHG tanks applications is expected to drive the filament winding CFRP market during the forecast period.

The COVID-19 pandemic has reduced the demand for CFRP tanks. Due to the lockdown situation, the demand for CFRP tanks has reduced from the gas transportation industry. The demand is expected to recover after the pandemic situation.

APAC is projected to be the fastest-growing CF & CFRP industry.

APAC is projected to be the fastest-growing CF & CFRP market during the forecast period. The region comprises countries such as Japan, China, South Korea, and Taiwan, having significant potential owing to the presence of established raw material suppliers, product manufacturers, and increasing new aircraft deliveries and wind energy installations in the region. There is a high demand for CF & CFRP from the wind energy, sporting goods, and aerospace industry in the region.

However, COVID-19 has negatively affected these industries in the APAC region. Japan, China, and Malaysia provide various components to aircraft manufacturers; China is the world's largest wind energy installer. The COVID-19 pandemic has resulted in less demand for the new aircraft and less wind energy installations, which are expected to reduce composite consumption in these countries in 2020.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights4.1 Attractive Opportunities in the CF & CFRP Market4.2 CFRP Market, by End-Use Industry and Region, 20194.3 Carbon Fiber Market, by Source4.4 Carbon Fiber Market, by Precursor Type4.5 CFRP Market, by Resin Type4.6 CFRP Market, by Manufacturing Process4.7 CFRP Market, by End-Use Industry4.8 CFRP Market, by Key Countries

5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Government Stimulus Packages for Aerospace and Other Industries for COVID-19 Crisis5.2.1.2 Increase in Demand for Fuel-Efficient Vehicles5.2.1.3 Increasing Demand from Wind Energy Industry5.2.2 Restraints5.2.2.1 Decrease in Number of Commercial Aircraft Deliveries5.2.2.2 Disruption in Supply Chain and Lower Production Capacity Utilization due to COVID-19 Pandemic5.2.2.3 High Cost of Carbon Fiber5.2.3 Opportunities5.2.3.1 Reduction in the Cost of Carbon Fiber5.2.3.2 Potential Opportunities in New Applications5.2.3.3 Growing Demand from Emerging Markets5.2.4 Challenges5.2.4.1 Maintaining Uninterrupted Supply Chain and Operating at Full Capacity5.2.4.2 Liquidity Crunch5.2.4.3 Development of Technology to Reduce Cycle Time5.3 Porter's Five Forces Analysis5.4 Value Chain Analysis5.5 Value Chain Analysis and Impact of COVID-195.6 Pricing Analysis5.7 Manuafturing Process Analysis5.8 Patent Analysis5.9 PESTEL Analysis5.10 Case Study

6 Macroeconomic Overview and Key Trends6.1 Introduction6.2 Trends and Forecast of GDP6.3 Impact of COVID-19 on Aerospace Industry6.3.1 Short-Term Strategies to Manage Cost Structure and Supply Chains6.3.2 New Opportunities6.4 Impact of COVID-19 on Automotive Industry6.4.1 Short-Term Strategies to Manage Cost Structure and Supply Chains6.4.2 Impact on Electric Vehicle (Ev) Demand due to Lower Oil Prices6.4.3 New Opportunities6.5 Impact of COVID-19 on Wind Energy Industry6.5.1 Short-Term Strategies to Manage Cost Structure and Supply Chains6.5.2 New Opportunities

7 Carbon Fiber Market, by Source7.1 Introduction7.2 Virgin Carbon Fiber7.2.1 Virgin Carbon Offers Better Thermal and Mechanical Properties Than Recycled Carbon Fiber7.3 Recycled Carbon Fiber7.3.1 Europe Leads the Demand for Recycled Carbon Fiber8 Carbon Fiber Market, by Precursor Type8.1 Introduction8.2 Polyacrylonitrile (Pan-Based) Carbon Fibers8.2.1 Pan-Based Carbon Fiber, by Tow Size8.2.1.1 Small-Tow (<24K)8.2.1.1.1 Small-Tow Carbon Fiber Finds Major Applications in Aerospace Industry8.2.1.2 Large-Tow (>24K)8.2.1.2.1 Wind Energy is Major Application of Large-Tow Carbon Fiber8.3 Pitch-Based Carbon Fiber8.4 Rayon-Based Carbon Fiber9 CFRP Market, by Resin Type9.1 Introduction9.2 Impact of COVID-19 on Resin Type9.3 Thermosetting CFRP9.3.1 Epoxy9.3.1.1 Epoxy Resin is Preferred in High-End Applications9.3.2 Vinyl Ester9.3.2.1 Vinyl Ester Resin Fin Applications in Transportation, Marine, and Pipe & Tank Industries9.3.3 Polyester9.3.3.1 Polyester is Cost-Competitive Resin9.3.4 Others9.4 Thermoplastic CFRP9.4.1 Polyetherethereketon (Peek)9.4.1.1 Peek Finds Extensive Use in Aerospace & Defense Applications9.4.2 Polyamide (Pa)9.4.2.1 Resistance to Wear, Heat, and Chemicals Supporting Growth of Polyamide Segment9.4.3 Polypropylene (Pp)9.4.3.1 Polypropylene-Based Thermoplastic Composites Have Huge Demand in Automotive Applications9.4.4 Others

10 CFRP Market, by Manufacturing Process10.1 Introduction10.2 COVID-19 Impact on Manufacturing Processes10.3 Lay-Up Process10.3.1 Aerospace & Defense End-Use Industry Drives the CFRP Market in Lay-Up Process10.4 Compression Molding Process10.4.1 Compression Molding Process Enables Short Cycle Time and a High Production Rate10.5 Resin Transfer Molding (Rtm) Process10.5.1 Rtm Process Used for Complex and Three Dimensional Components10.6 Filament Winding Process10.6.1 Pipe & Tank End-Use Industry Drives the CFRP Market in Filament Winding Process10.7 Injection Molding Process10.7.1 Automotive and Electrical & Electronics End-Use Industries Drives the CFRP Market in Injection Molding Process10.8 Pultrusion Process10.8.1 Wind Energy End-Use Industry is Largest Consumer of CFRP Pultruded Components10.9 Other Processes

11 CFRP Market, by End-Use Industry11.1 Introduction11.2 Aerospace & Defense11.2.1 Interior Parts11.2.1.1 Phenolic and Thermoplastic Composites Mainly Used in Aircraft Interior Structures11.2.2 Exterior Parts11.2.2.1 Fuselage, Wings, Rotor Blades, Tail Boom, and Radomes are Major Exterior Parts11.3 Wind Energy11.3.1 Wind Blades11.3.1.1 Carbon Fiber Widely Used for Making Spar Caps11.4 Automotive11.4.1 Interior Parts11.4.1.1 Seat Backs, Headliners, Package Trays, and Dashboards are Major Automotive Interior Parts11.4.2 Exterior Parts11.4.2.1 Exterior Parts are Major Applications in Automotive Industry11.5 Sporting Goods11.5.1 APAC Leads the Demand in Sporting Goods Industry11.6 Civil Engineering11.6.1 Restorations of Old Structures Driving the Use of Carbon Fiber11.7 Pipe & Tank11.7.1 Increase in Demand for Type Iv Cylinders Driving the CFRP Market11.8 Marine11.9 Electrical & Electronics11.9.1 APAC Leads Demand in Electrical & Electronics Segment11.10 Medical11.10.1 COVID-19 Pandemic Has Increased Demand for CFRP Materials in Medical Industry11.11 Other End-Use Industries12 CFRP Market, by Region12.1 Introduction12.2 North America12.4 APAC12.5 Latin America12.6 MEA (Middle East & Africa)

13 Competitive Landscape13.1 Introduction13.2 Market Share Analysis13.3 Market Evaluation Framework13.3.1 Expansion13.3.2 Agreement13.3.3 Acquisition13.3.4 Product Launch/Technology Launch13.3.5 Partnership13.3.6 Joint Venture13.3.7 Collaboration13.4 Revenue Analysis of Top Market Players, 201913.5 Company Evaluation Matrix13.5.1 Star13.5.2 Pervasive13.5.3 Participant13.5.4 Emerging Leaders13.6 Strength of Product Portfolio13.7 Business Strategy Excellence

14 Company Profiles14.1 Toray Industries Inc.14.2 Teijin Limited14.3 Mitsubishi Chemical Holdings Corporation14.4 Hexcel Corporation14.5 Solvay Group14.6 Sgl Group14.7 Formosa Plastics Corporation14.8 Hyosung14.9 Zhongfu Shenying Carbon Fiber Co., Ltd.14.10 Kureha Corporation14.11 Dowaksa14.12 Taekwang Industrial Co. Ltd.14.13 Jiangsu Hengshen Co., Ltd.14.14 Elg Carbon Fibre Ltd.14.15 Nippon Graphite Fiber Corporation14.16 Plasan Carbon Composites14.17 Kemrock Industries and Exports Ltd.14.18 Hindoostan Composite Solutions14.19 Crosby Composites14.20 Sigmatex Limited14.21 Zhongao Carbon14.22 Aeron Composite Pvt. Ltd.14.23 Weihai Tuozhan Fibers Co. Ltd.14.24 Cfk Valley Stade Recycling GmbH & Co. Kg14.25 Alabuga Fiber, LLC

15 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/k9jygd

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post here:

CF & CFRP Market by Source, Precursor, Resin, Manufacturing Process, End-use Industry, and Region - Global Forecast to 2025 - Yahoo Finance

Vertex Pharmaceuticals (VRTX) has done well to help many patients in the cystic fibrosis (CF) community. The problem is that it has more patients to cover and to potentially improve treatment upon. Well, it has generated another partnership with Moderna (MRNA) for developing a potential gene editing therapy for the treatment of patients with cystic fibrosis. This is the second collaboration that provides an additional shot on goal. I believe this is a good move for Vertex as it looks to expand its presence in the CF space. It is imperative that Vertex moves to do this to address the patients that don't respond to its current therapies. Since Vertex's CFTR modulators only target those CF patients who produce the CFTR protein, about 10% don't respond to its drugs. A mode of action of developing a gene-edited therapy to address this issue is plausible. That's why I believe Vertex has the potential to eventually expand its market with this latest deal. There was another deal made with Moderna years earlier that is also progressing as well. This is why I think it's worth a look as a speculative investment.

Vertex Pharmaceuticals and Moderna Pharmaceuticals made an agreement, whereby Moderna would use its lipid nanoparticle (LNP) technology to develop gene-edited therapies to treat patients with cystic fibrosis. This is not a bad agreement at all. That's because Vertex is only paying $75 million upfront for this collaboration and then up to $380 million in additional milestone payments. This means Moderna will be responsible for starting off research activities of its LNP technologies to hopefully make something suitable to bring into the clinic in human testing. Vertex will help a little bit in the research by providing gene editing that is supposed to be incorporated into the LNPs being developed. This isn't the only deal that Vertex made to advance another potential CF drug. Back in 2016, Vertex made another deal, whereby Moderna would use its mRNA technology to deliver a gene-edited therapy for the treatment of patients with CF. This other deal was a multi-year agreement with a $20 million upfront payment and then $20 million in a Moderna convertible note that was to be converted to equity. From there, it would be about $275 million in milestone payments. The bottom line here is that there are two delivery approaches being made to deliver gene-edited therapies. Both LNP and mRNA have the potential to deliver the gene that CF patients need to develop the CFTR protein. As I noted in the beginning, despite several CFTR modulators that Vertex markets, there are 10% of patients who don't benefit at all from them. That means these gene-edited therapies may potentially allow these nonresponder patients to respond.

According to the 10-Q SEC Filing, Vertex Pharmaceuticals had cash, cash equivalents, and marketable securities of $5.5 billion as of June 30, 2020. It has a huge cash runway to fund its pipeline and meet its commitments. Not only that, but I don't foresee the need to also do a major cash raise. The reason why is that, if necessary, it can tap into a revolving credit facility that was done in 2019. That is, it can borrow up to $500 million according to this agreement. There are several benefits here with this agreement that are also a huge plus. This includes the ability to repay and reborrow without penalty. In addition, if it is ultimately needed, Vertex can ask the borrowing capacity to be increased by another $500 million. That would bring the possible borrowing power to $1 billion. Of course, that's only an option if Vertex really needs additional cash. However, Vertex is already producing substantial amounts of revenue. For its Q2 of 2020 earnings, it reported product revenues of $1.52 billion. That's substantial because that is a 62% increase compared to the same time period in 2019. That is not the only thing that should give investors confidence. Another positive development is that the company raised its full-year 2020 guidance higher. It originally was expecting full-year 2020 CF revenues of $5.3-5.6 billion. However, with increasing sales, it is now guiding its full-year 2020 CF revenues to be $5.7-5.9 billion.

The latest collaboration agreement between Vertex and Moderna is still risky. That's because this is only starting off in the research phase and where preclinical studies must be done first in animal testing. There is no guarantee that any candidate/s will make it to human clinical testing. If that happens, then it's possible that either the first or second collaboration agreement could be terminated. The good news is that there are two routes that will be attempted. One route is to use LNPs to deliver gene-edited CFTR protein and then the other one will use messenger RNA (mRNA) delivery technology instead. As long as one delivery tech candidate is successful, that will be good news for both patients and investors. On the flip side, as I have shown, Vertex is already producing substantial revenues from its currently marketed CFTR modulator drugs. A second risk could be an eventual slowdown in revenues because of the situation with Covid-19; however, that hasn't had a dramatic impact on sales as of yet.

Vertex Pharmaceuticals is a good buy based on its recent performance in sales. As noted above, sales year over year in Q2 2020 increased by 62% to $1.52 billion. Not only that but guidance was also increased as well. The recent deal with Moderna, plus the one made several years ago, has the potential to help the company expand its presence in the CF space. While many benefit from Vertex's CFTR modulator drugs currently available, there are many who still don't. Even then, the company is also expanding its current CFTR modulator therapies to other subpopulation of patients. For example, it recently received FDA approval of KALYDECO for use in CF patients who are aged 4 to less than 6 months that have at least 1 mutation in their CFTR gene. KALYDECO was already approved for use in the U.S. and EU in CF patients, however, that was for patients aged 6 months and older. This latest regulatory approval will allow Vertex to treat an additional group of patients it couldn't target before. For all these reasons, that's why I think Vertex is worth a look as a speculative buy.

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more from the original source:

Vertex Looks To Target 10% Of Cystic Fibrosis Population Not Yet Achieved By Its Current CFTR Modulators - Seeking Alpha

Leyland Trucks has completed the build of its 100,000th DAF CF / XF truck: a CF 530 FAT 64 drawbar chassis. The truck is part of a batch of four vehicles ordered by DAF Trucks Australia and is shortly to be exported, specd for the countrys fuel tanker market.

The state-of-the-art Leyland production facility has been producing DAF-branded commercial vehicles since the late eighties. Nowadays, Leyland Trucks builds the full range of market-leading DAF LF, CF and XF chassis in any configuration. Most of the CF and XF trucks that leave the assembly line are produced for Right Hand Drive markets, such as the UK and Australia. The plant recently received the coveted Queens Award for Enterprise 2020 for increasing exports by almost 50% over the last three years.

Landmark momentThis 100,000th CF and XF truck produced at the Leyland Assembly Plant is a hugely significant milestone for Leyland Trucks, said Leyland Trucks managing director Brennan Gourdie. There is a proud heritage of truck building in the UK and at Leyland, culminating with the production of the current line-up of DAF trucks today. 100,000 CF and XF chassis is a landmark moment representing an exceptional commitment from everyone here at Leyland and from the wider DAF organization world-wide.

SOURCE: DAF

Read more from the original source:

Leyland Trucks builds 100000th DAF CF / XF truck - Automotive World

Tampa Bay center fielder Kevin Kiermaier departed the Rays' American League Championship Series game against the Houston Astros on Tuesday with a bruised left hand, but he said after the game he is focused on getting back into the lineup.

Kiermaier got hurt when he was hit by a pitch in the sixth inning.

Appearing on the TBS postgame show with his hand and wrist wrapped, the Rays having just won 5-2 to take a 3-0 series lead in San Diego, Kiermaier was able to laugh about the injury.

"It feels like I got hit by 99 (mph) right in the wrist," he joked. "But we'll be OK. We got great trainers here. (I'll) try to recover as quick as I can, but it feels like how it should I feel like after getting hit by 99."

"Try to be hockey tough," he added.

Kiermaier yelled out loudly after the 0-2 fastball by Houston right-hander Enoli Paredes hit the hand. He was examined by trainers and initially stayed in the game and scored one of the runs in Tampa Bay's five-run inning.

But Kiermaier, a two-time Gold Glove winner, didn't take the field for the bottom of the sixth as he instead went to get X-rays. Hunter Renfroe, who pinch-hit during the sixth inning, stayed in the game in right field as Manuel Margot moved to center.

TBS soon reported that X-rays were negative.

Kiermaier was 0-for-2 with a strikeout before exiting. He is 2-for-9 in the series.

Now, more than ever, the world needs trustworthy reportingbut good journalism isnt free.Please support us by subscribing or making a contribution today.

Originally posted here:

Rays CF Kiermaier departs with hand injury | Sportsxchange - Rockdale Newton Citizen